Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Apr 29, 2024
Deals

Ono’s $2.4B Deciphera buy adds two cancer therapies, grows U.S. presence

With end of Opdivo’s exclusivity on the horizon, Japanese pharma continues to take steps in global expansion
BioCentury | Nov 19, 2020
Finance

VCs back Celleron spinout with €37M to develop former Roche asset for rare joint disorder

A European VC syndicate shared Celleron’s belief that a single-asset start-up was the best place to develop emactuzumab, an asset the U.K. biotech obtained after Roche deprioritized it in 2018.
BioCentury | May 24, 2019
Product Development

Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals

Despite ODAC’s snub of quizartinib, Daiichi has several moves to make its 2025 cancer drug goals
BioCentury | Feb 9, 2018
Emerging Company Profile

Fast boat to China

Abbisko aims to be first to market in China with ‘me better’ cancer compounds
Items per page:
1 - 10 of 14